Recent quarterly results from Omnicell (OMCL) topped expectations for both revenue and profit, prompting analysts to lift their outlook and tighten consensus around higher earnings estimates and continued positive ratings.

Omnicell’s share price has gained 18.84% over the past month and 12.26% over the past quarter. The year-to-date share price return is slightly down 1.62%, and the 1-year total shareholder return of 57.31% contrasts with longer term 3- and 5-year total shareholder returns that are significantly lower. This suggests recent momentum is building from a weaker multi year base.

If upbeat earnings have you looking beyond a single stock, it could be a good moment to broaden your search with healthcare focused AI opportunities through the 34 healthcare AI stocks.

With the stock up sharply in recent months, analysts highlighting a sizeable gap to their average price target and earnings estimates moving higher, you now face the key question: is Omnicell undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 27.5% Undervalued

Omnicell's most followed valuation story puts fair value at $61.29 versus a last close of $44.41, so the narrative assumes a meaningful gap that future fundamentals could close.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Curious what sits behind that earnings ramp, margin lift, and rich future P/E that underpin this fair value? The narrative leans on specific growth, profitability, and discount rate assumptions that could materially change how you see $61.29 versus $44.41.

Result: Fair Value of $61.29 (UNDERVALUED)

However, this story can change quickly if tariff costs stay elevated or if hospitals trim capital budgets, which could pressure Omnicell’s margins and large-system deals.

Another Way To Look At Valuation

That 27.5% “undervalued” story sits awkwardly next to Omnicell’s current P/E of 98.8x. The Medical Equipment industry sits at 24.5x and peers at 33.5x, while the fair ratio points to 35.2x. That is a big gap. Is it a genuine opportunity, or just extra valuation risk?

Next Steps

With sentiment split between strong recent returns and a rich P/E, it makes sense to look under the hood yourself and move quickly while opinions differ. To see what is driving optimism around the stock, take a closer look at the 3 key rewards.

Looking for more investment ideas?

If Omnicell has your attention, do not stop here. Broaden your watchlist now so you are not chasing the next opportunity after it has already moved.

• Spot potential value early by checking stocks that currently look attractively priced using the 49 high quality undervalued stocks.
• Prioritize resilience by reviewing companies with stronger balance sheets through the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for under-the-radar opportunities by scanning the screener containing 21 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.